Amyloid-beta binding proteins
First Claim
Patent Images
1. An anti-Aβ
- (20-42) globulomer antibody that comprises a heavy chain variable region and a light chain variable region, whereina) the heavy chain variable region comprises complementary determining region (CDR) H1, CDRH2, and CDRH3 of SEQ ID NO;
17, SEQ ID NO;
18, and SEQ ID NO;
19, respectively, and the light chain variable region comprises CDRL1, CDRL2, and CDRL3 of SEQ ID NO;
20, SEQ ID NO;
21, and SEQ ID NO;
22, respectively;
b) the heavy chain variable region comprises CDRH1,CDRH2, and CDRH3 of SEQ ID NO;
33, SEQ ID NO;
34, and SEQ ID NO;
35, respectively, and the light chain variable region comprises CDRL1, CDRL2, and CDRL3 of SEQ ID NO;
36, SEQ ID NO;
37, and SEQ ID NO;
38, respectively;
c) the heavy chain variable region is at least 90% identical to SEQ ID NO;
1, 3, 4, 6, 7, 8, 9, 10, 11, 12, or 13, and the light chain variable region is at least 90% identical to SEQ ID NO;
2, 5, 14, 15, or 16;
ord) the heavy chain variable region is at least 90% identical to SEQ ID NO;
25, 27, 29, or 30, and the light chain variable region is at least 96% identical to SEQ ID NO;
26, 28, 31, or 32.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Λβ(20-42) globulomer or any Λβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
415 Citations
18 Claims
-
1. An anti-Aβ
- (20-42) globulomer antibody that comprises a heavy chain variable region and a light chain variable region, wherein
a) the heavy chain variable region comprises complementary determining region (CDR) H1, CDRH2, and CDRH3 of SEQ ID NO;
17, SEQ ID NO;
18, and SEQ ID NO;
19, respectively, and the light chain variable region comprises CDRL1, CDRL2, and CDRL3 of SEQ ID NO;
20, SEQ ID NO;
21, and SEQ ID NO;
22, respectively;b) the heavy chain variable region comprises CDRH1,CDRH2, and CDRH3 of SEQ ID NO;
33, SEQ ID NO;
34, and SEQ ID NO;
35, respectively, and the light chain variable region comprises CDRL1, CDRL2, and CDRL3 of SEQ ID NO;
36, SEQ ID NO;
37, and SEQ ID NO;
38, respectively;c) the heavy chain variable region is at least 90% identical to SEQ ID NO;
1, 3, 4, 6, 7, 8, 9, 10, 11, 12, or 13, and the light chain variable region is at least 90% identical to SEQ ID NO;
2, 5, 14, 15, or 16;
ord) the heavy chain variable region is at least 90% identical to SEQ ID NO;
25, 27, 29, or 30, and the light chain variable region is at least 96% identical to SEQ ID NO;
26, 28, 31, or 32. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- (20-42) globulomer antibody that comprises a heavy chain variable region and a light chain variable region, wherein
Specification